Calithera Biosciences Inc., of South San Francisco, reported results from a phase I trial testing CB-839, an inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple-negative breast cancer (TNBC) at the 2017 San Antonio Breast Cancer Symposium in San Antonio Of the 37 evaluable patients treated with at least 600 mg of CB-839 twice a day, there were eight partial responses (22 percent), and disease control, defined as response or stable disease, was seen in 22 patients (59 percent).